icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Synergistic Interactions of HCV NS5A Replication Complex Inhibitors Sensitize Resistant Variants and Enhance the Efficacy of Daclatasvir (DCV, BMS-790052) In Vitro and In Vivo
 
 
  Reported by Jules Levin
EASL 2013 April 26 Amsterdam
 
Gao M, O'Boyle II DR, Lemm JA, Fridell RA, Wang C, Roberts S, Liu M, Nower P, Wang Y-K, Johnson BM, Kramer M, Moulin F, Nophsker MJ, Hewawasam P, Kadow J, Cockett M, Meanwell NA, Belema M, Sun JH Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
 
"PXB mice (PhoenixBio) were infected with GT 1a and treated orally with BMS-393 +/- Syn or Syn alone for up to 2 weeks" from Jules: a synergist molecule has been developed & being studied by BMS in combination with BMS052, their NS5A, which will it is hoped prevent resistance & reverse resistance associated with BMS052 & thus these 2 drugs would be used together as part of a combination oral therapy

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif